tiprankstipranks
Gilead exercises option to exclusively license NX-0479 from Nurix Therapeutics
The Fly

Gilead exercises option to exclusively license NX-0479 from Nurix Therapeutics

Gilead (GILD) and Nurix Therapeutics (NRIX) announced that Gilead has exercised its option to exclusively license Nurix’s investigational targeted protein degrader molecule NX-0479. This bivalent degrader, designated GS-6791, is the first development candidate resulting from the previously announced Nurix-Gilead collaboration to discover, develop, and commercialize a pipeline of innovative targeted protein degradation therapies. Under the terms of the parties’ collaboration, option and license agreement, for the NX-0479 option that Gilead is exercising, Nurix will receive an option exercise payment of $20M and potentially could receive up to an additional $425M in clinical, regulatory, and commercial milestone payments, as well as up to low double-digit tiered royalties on product net sales.

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on GILD:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles